J. Boncela et al., Acute phase protein alpha(1)-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity, J BIOL CHEM, 276(38), 2001, pp. 35305-35311
alpha (1)-Acid glycoprotein, one of the major acute phase proteins, was fou
nd to interact with plasminogen activator inhibitor type 1 (PAI-1) and to s
tabilize its inhibitory activity toward plasminogen activators. This conclu
sion is based on the following observations: (a) alpha (1)-acid glycoprotei
n was identified to bind PAI-1 by a yeast two-hybrid system. Three of 10 po
sitive clones identified by this method to interact with PAI-1 contained al
most the entire sequence of alpha (1)-acid glycoprotein; (b) this protein f
ormed complexes with PAI-1 that could be immunoprecipitated from both the i
ncubation mixtures and blood plasma by specific antibodies to either PAI-1
or alpha (1)-acid glycoprotein. Such complexes could be also detected by a
solid phase binding assay; and (c) the real-time bimolecular interactions m
onitored by surface plasmon resonance indicated that the complex of alpha (
1)-acid glycoprotein with PAI-1 is less stable than that formed by vitronec
tin with PAI-1, but in both cases, the apparent KD values were in the range
of strong interactions (4.51 + 1.33 and 0.58 + 0.07 nm, respectively). The
on rate for binding of PAI-1 to ai-glycoprotein or vitronectin differed by
2-fold, indicating much faster complex formation by vitronectin than by al
pha (1)-acid glycoprotein. On the other hand, dissociation of PAI-1 bound t
o vitronectin was much slower than that from the alpha (1)-acid glycoprotei
n, as indicated by 4-fold lower k(off) values. Furthermore, the PAI-1 activ
ity toward urokinase-type plasminogen activator and tissue-type plasminogen
activator was significantly prolonged in the presence of alpha (1)-acid gl
ycoprotein. These observations suggest that the complex of PAI-1 with alpha
(1)-acid glycoprotein can play a role as an alternative reservoir of the p
hysiologically active form of the inhibitor, particularly during inflammati
on or other acute phase reactions.